Are GLP-1s on the verge of becoming pharma’s biggest segment? Yes and no. It depends whether you’re watching products or categories. And in terms of individual drugs, it likely depends on the year. Oncology is still on top for now. On the product level, according to Evaluate’s 2028 projections, Keytruda will maintain its lead at… The post Are GLP-1s about to dethrone oncology as pharma’s biggest segment? Not for a few years yet appeared first on Drug Discovery and Development.| Drug Discovery and Development
The pharmaceutical blockbuster model is wobbling. And no single franchise is safe. While king Keytruda, Merck’s stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S. patent expiry in 2028 the single biggest loss of exclusivity event on the horizon. In the U.S., Medicare… The post Top 25 drugs by sales: 2025 H1 appeared first on Drug Discovery and Development.| Drug Discovery and Development
Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today. Around 5,000 positions are expected to be cut in Denmark. This will reduce the company’s workforce from its current 78,400 positions to approximately 69,400. The company’s stock has fallen about 58% over the past year as… The post Novo Nordisk to cut 9,000 jobs globally to compete in GLP-1 market appeared first on Drug Discovery and Development.| Drug Discovery and Development